OpenAI releases the GPT-4b Micro model, a model that may allow you to live longer!

OpenAI has set its sights on the life sciences this time around, partnering with Retro Biosciences, a company dedicated to extending life expectancy, to launch a new AI model - theGPT-4b MicroThe

This breakthrough technology may reshape the rules of protein design with the goal of optimizing and redesigning proteins, opening up unprecedented possibilities for regenerative medicine.

1. Yamanaka factor change: 50 times more efficient

Yamanaka factor, known as the "magic key" of regenerative medicine, resets adult cells into pluripotent stem cells.

There was a study where muscle stem cells from an aging mouse were repaired with a protein and then re-transplanted back into the mouse, which was surprisingly rejuvenated! The protein was Yamanaka factor.

However, the "inefficiency" of the factor has always been a bottleneck in its application, and GPT-4b Micro proposes a modification of the Yamanaka factor through a unique algorithmic design, which improves its efficiency by50 times over, this result has been verified in preliminary experiments.

This breakthrough is not just an advancement in scientific theory, but also has a very high potential for application. For example, with optimized cell reprogramming techniques, it is possible to repair damaged retinas or treat chronic diseases such as diabetes. This ability to design proteins with precision and efficiency opens up new possibilities in regenerative medicine.

2. More than structure prediction: GPT-4b Micro is different from AlphaFold

Unlike AI models such as AlphaFold that focus on protein structure prediction, GPT-4b Micro focuses on protein function optimization, especially in protein interactions. In this way, it provides scientists with new tools for transforming and designing proteins, leading to rapid translation from basic research to clinical applications.

Joe Bates Lacroix, CEO of Retro Biosciences, pointed out that the proteins designed by the model showed significant reprogramming efficiency improvements in experiments, far exceeding traditional design solutions. This signifies that AI is transforming from a "theoretical helper" to an "experimental partner".

3. From technology vision to business ambition

It's not just the collaboration of scientists behind this project, but also the strategic placement of OpenAI. Altman has a deep interest in longevity research and even invested in Retro Biosciences for the$180 million, an action that shows his dedication to entering the anti-aging field.

The successful launch of GPT-4b Micro also further demonstrates the potential of AI technology in the field of bioengineering. Whether it is accelerating the experimental process or optimizing protein design, it demonstrates the important role of AI in breaking through life science challenges.

4. Embracing a new era in medicine

From structural elucidation, represented by AlphaFold, to functional optimization, driven by GPT-4b Micro, the progress of AI in the biological field is becoming more concrete and practical. Protein engineering, a field that was once complex and required a lot of trial and error, is now becoming more efficient and precise with the addition of AI.

The introduction of the GPT-4b Micro is a new beginning that not only shows the possibilities of AI in biotechnology, but also paints a picture of a bright future: helping humans to overcome aging and cure diseases by redefining the state of cells.At some point in the future, AI may actually help us live longer and even change the nature of human existence.